Interim report 1 January - 31 March 2010
 § Local currency sales increased by 4% and Euro sales increased by 6% to
€361.9m (€341.3m).
§ Average size of the sales force increased by 12% to 3.5m consultants and
closing sales force was up by 6%.
§ EBITDA amounted to €49.3m (€43.3m).
§ Operating margin before restructuring costs increased to 11.7% (11.1%)
resulting in an operating profit of €42.2m (€37.9m).
§ Net profit before restructuring costs increased to €37.2m (€24.2m). § EPS
after dilution and before restructuring costs amounted to €0.65 (€0.43).
§ Cash flow from operating activities amounted to €20.7m (€12.6m).
§ Oriflame completed a $165m issue of private placement notes after the close
of the period.
"As we have communicated earlier, the first half of 2010 will be challenging
with tough comparables. This has proven true as growth in the first quarter was
rather modest. However, we are comfortable with our outlook for 2010 of around
10% sales growth with an operating margin above 12% at current exchange rates.
Given the growth at the start of the year, we will focus our resources even more
towards top line growth. On the positive side, we see that currencies are moving
strongly in our favour and if that remains it will have a positive effect on our
operating margins for 2010," CEO Magnus Brännström comments.
[HUG#1406036]
Oriflame Q1 2010 Report, PDF:
http://hugin.info/134730/R/1406036/359681.pdf
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.